Lexaria Bioscience (LEXX) Cash & Current Investments (2010 - 2026)

Lexaria Bioscience has disclosed Cash & Current Investments across 17 years of filings, most recently posting $5.1 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $5.1 million, down 21.62% year-over-year; the trailing twelve-month figure through Feb 2026 was $5.1 million (down 21.62% YoY), and the FY2025 annual result was $1.9 million, down 70.33% from the prior year.
• Cash & Current Investments came in at $5.1 million for Q1 2026 at Lexaria Bioscience, up from $4.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $8.9 million in Q1 2022 to a low of $1.5 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $4.8 million (2022), against an average of $5.2 million.
• Across the five-year window, Cash & Current Investments plunged 76.01% in 2023 and jumped 343.63% in 2024, its largest moves.
• Lexaria Bioscience's Cash & Current Investments stood at $4.8 million in 2022, then plunged by 57.8% to $2.0 million in 2023, then jumped by 300.58% to $8.1 million in 2024, then sank by 45.5% to $4.4 million in 2025, then rose by 15.9% to $5.1 million in 2026.
• The last three Cash & Current Investments figures came in at $5.1 million (Q1 2026), $4.4 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.